Differential expression of cell cycle regulators in phenotypic variants of transgenically induced bladder tumors:

Antonio Garcia-España1, Edgard Salazar, Tung-Tien Sun

  • 1Department of Pathology, New York University Cancer Institute, New York, USA.

Cancer Research
|March 1, 2005
PubMed

Insights

Investigating cell cycle regulators in mouse bladder tumors revealed distinct patterns. These differences in cell cycle control may explain varying tumor progression, offering insights for targeted therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Deregulation of cell growth, differentiation, apoptosis, and oncogenic stress proteins is common in tumors.
  • The impact of these deregulations on tumor behavior is not fully understood across all tumor types.
  • Transgenic mouse models expressing activated H-ras or SV40 T antigen mimic human bladder tumors.

Purpose of the Study:

  • To assess cell cycle regulator expression in distinct transgenic mouse bladder tumor models.
  • To correlate cell cycle profiles with tumor behavior and progression potential.
  • To evaluate the utility of these models for therapeutic strategy development.

Main Methods:

  • Analysis of cell cycle regulator expression in wild-type, cyclin D1 transgenic, H-ras transgenic, and SV40 T antigen transgenic mouse bladders.
  • Assessment of key cell cycle proteins including Rb family, cyclins (A, E), CDKs, p16, p53, and MDM2.
  • Comparison of molecular profiles between different tumor types and normal urothelium.

Main Results:

  • Cyclin D1 overexpression in urothelium did not alter the quiescent cell cycle profile.
  • H-ras-induced papillary tumors showed loss of Rb family proteins and late cyclins/CDKs, with increased p16, p53, and MDM2.
  • SV40 T antigen-induced carcinoma in situ displayed increased expression of post-G(1) phase cell cycle regulators.

Conclusions:

  • Inactivation of the Rb pathway is crucial in H-ras-driven superficial papillary tumors.
  • Oncogenic H-ras may activate alternative tumor suppressor pathways.
  • Distinct cell cycle profiles in different bladder tumor types correlate with their progression potential, validating transgenic models for therapeutic research.